1. Lammert M, Friedman JM, Kluwe L, et al. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 2005;141:71-4.
2. Ortonne N, Wolkenstein P, Blakeley JO, et al. Cutaneous neurofibromas: current clinical and pathologic issues. Neurology 2018;91:S5-13.
4. Vogel AC, Gutmann DH, Morris SM. Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol 2017;59:1112-6.
5. Domon-Archambault V, Gagnon L, Benoit A, et al. Psychosocial features of neurofibromatosis type 1 in children and adolescents. J Child Neurol 2018;33:225-32.
7. Kim KI, Won HT, Lee JH, et al. Standardization study of symptom check list-90 in Korea I: characteristics of normal responses. J Korean Neuropsychiatr Assoc 1978;17:449-58.
8. Kim JH, Kim GI. The standardization study of Symptom Checklist-90-revision in Korea III. Ment Health Res 1984;2:278-311.
9. Kim JH, Kim KI, Lee HR. The code patterns of Korean version of the Symptom Checklist-90-revision. Ment Health Res 1985;3:173-217.
12. Kim IH, Kim CY, Kim KH, et al. Analysis of female lichen planus patients with SCL-90-R. J Oral Med Pain 2011;36:235-43.
13. Jin SM, Ban JH, Lee SH, et al. Psychologic charateristics of patients with vocal nodules: an investigation using the Symptom Checklist-90-revision. Korean J Otorhinolaryngol Head Neck Surg 2000;43:86-9.
14. Ko MY, Kim CY, Jeon HM, et al. Psychological analysis of recurrent aphthous ulcer patients with SCL-90-R. J Oral Med Pain 2012;37:19-25.
15. Yun YH, Lee SH, Choi JH. Neurocognitive function in patients with Hwa-byung and with major depressive disorder. Korean J Biol Psychiatry 2005;12:181-8.
17. Won HT, Kim JH, Oh KJ, et al. Korean manual of Symptom Checklist-90 Revision (SCL-90-R). Seoul: Huno; 2015.
18. McNeill AM, Hudock RL, Foy AMH, et al. Emotional functioning among children with neurofibromatosis type 1 or Noonan syndrome. Am J Med Genet A 2019;179:2433-46.
19. Lai JS, Jensen SE, Charrow J, et al. Patient reported outcomes measurement information system and quality of life in neurological disorders measurement system to evaluate quality of life for children and adolescents with neurofibromatosis type 1 associated plexiform neurofibroma. J Pediatr 2019;206:190-6.
21. Grande TL, Newmeyer MD, Adair ES. Symptom differences by gender for outpatient clients as measured by the SCL-90-R. Michigan J Couns Res 2013;40:4-13.
22. Ablon J. Gender response to neurofibromatosis 1. Soc Sci Med 1996;42:99-109.
23. Merker VL, Bredella MA, Cai W, et al. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A 2014;164A:1431-7.
24. Granstrom S, Langenbruch A, Augustin M, et al. Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology 2012;224:160-7.